Research
Reach2HD Recruiting Now
Reach2HD is a Phase 2 study to determine the safety, tolerability and efficacy of PBT2 in patients with early to mid-stage Huntington’s disease currently recruiting participants.
Research has shown that normally occurring metals in the brain play a significant role in diseases such as HD. PBT2 has been demonstrated to interrupt interactions between biological metals and target proteins in the brain to prevent the deterioration of brain cells in animal models and Alzheimer’s patients, therefore it may improve cognition.
Locations: Nine Research Centers in the United States. (See list and contact information below).
Participants: A total of 100 participants are needed.
• Age: 25 or older
• Early to mid-HD, with a genetic test CAG repeat equal or greater than 36, motor symptoms of HD and a Total Functional Capacity Subscale Score (TFC) between 6 and 13
• Have a cognitive impairment as demonstrated by a MoCa score of equal or greater than 12
• Each participant must have a study partner who is willing to provide consent and spends on average at least 2 hours a day for at least four days a week with the patient and agrees to attend certain visits and provide accurate information about the patient.
• Participants must be able to swallow oral capsules, and if they are taking tetrabenazine, must have been on a stable dose for at least 3 months.
• Participants may not have an allergy to PBT2 or other primary neurodegenerative disorders association with dementia, or any other condition that may impair cognition. They may not have chronic heart, kidney, blood, liver conditions, or have been diagnosed with a malignancy within 2 years of screening. Pregnant or lactating females may not participate as well.
Trial Duration: 34 weeks and a total of 8 participant visits including a final follow-up visit. At these visits there will be blood drawn and other tests performed, and at three there will be an eye exam. Study partners will be required to attend 3 visits with the subject.
There are travel reimbursements available for participants. Please speak to the site coordinator about details.
For more details please call one of the participating sites. For more information regarding this study please visit:
http://www.clinicaltrials.gov/ct2/show/NCT01590888? term=Reach2hd&rank=1
Locations
|
United States, California |
|
|
University of California San Diego |
|
|
San Diego, California, United States, 92161 Jody Goldstein: 858-246-1254 |
|
|
United States, Colorado |
|
|
Colorado Neurological Institute |
|
|
Englewood, Colorado, United States, 80113 |
|
|
Diane Erickson: 303-762-6674 |
|
|
United States, Maryland |
|
|
Johns Hopkins University Baltimore, Maryland, United States Nadine Yoritomo 410-614-9254
University of Maryland School of Medicine |
|
|
Baltimore, Maryland, United States, 21201 |
|
|
Samantha Gibson: 410-328-4349 |
|
|
United States, Minnesota |
|
|
Struthers Parkinson's Center |
|
|
Golden Valley, Minnesota, United States, 55427 |
|
|
Patricia Edo: 952-993-5495
|
|
|
United States, Missouri |
|
|
Washington University |
|
|
St. Louis, Missouri, United States, 63110 |
|
|
Patricia Deppen: 314-362-8548
|
|
|
United States, New York |
|
|
Albany Medical College |
|
|
Albany, New York, United States, 12208 |
|
|
Mary Eglow: 518-262-6611
|
|
|
Columbia University Medical Center |
|
|
New York City, New York, United States, 10032 |
|
|
Ronda Couse: 212-305-2387
|
|
|
United States, Tennessee |
|
|
University of Tennessee Health Science Center |
|
|
Memphis, Tennessee, United States, 38163 |
|
Kate Marshall: 901-448-6180